晚期非小细胞肺癌化疗效果与化疗敏感性研究  

Study on Effect of Advanced Non-small Cell Lung Cancer by Chemotherapy and Its Chemotherapeutic Sensitivity

作　　者：韩芳[1] 丁昌平[1] 王丽[1] 童建东[1] 

机构地区：[1]江苏省扬州市第一人民医院肿瘤科,江苏扬州225001

出　　处：《中外医疗》2015年第18期76-77,共2页China & Foreign Medical Treatment

摘　　要：目的探讨分析晚期非小细胞肺癌化疗的效果以及化疗敏感性。方法随机选取2009年6月—2011年7月该院收治的100例晚期非小细胞肺癌患者的临床资料,随机分成4个小组,分别采取TP、DP、GP、NP的化疗方案,对其中的5例患者进行9mTX-MIBI检查,观察四种化疗方案的总有效率和4组患者的生存率,观察影像检查结果中疗效和阳性之间的关系。结果TP组和DP组的治疗有效率高于GP、NP组(40.0%、40.0%vs32.0%、28.0%),患者1年生存率也较高(44.0%、48.0%vs32.0%、32.0%)。9mTc-MIBI检查结果为阴性不能排除患病的可能。结论TP方案和DP方案在治疗有效率以及治疗后患者的生存率上均有明显优势,即使9mTc-MIBI检查结果为阴性。仍需完善相关的检查项目或进行临床观察。Objective To study the effect of advanced non small cell lung cancer by chemotherapy and its chemotherapeutic sensitivity. Methods The clinical data of 100 patients with advanced non-small cell lung cancer admitted in our hospital between June 2009 and July 2011 were randomly into four groups, receiving chemotherapy of TP、DP、GP、NP respectively. Five patients of them were detected by 9mTc-MIBI. The total effective rates and survival rates of the four groups by different chemotherapy regimens, and the relationship between curative effect and the positive showed by the imaging results, were observed. Results The treatment efficient of the TP and DT group was higher than that of the GP and NP group （40.0%, 40.0% vs 32.0%, 28.0%, and patients＇ survival rate was higher （44.0%, 48.0% vs 32.0%, 32.0%）, too. Negative results by 9mTc-MIBI test could not rule out the possibility of disease. Conclusion The effective rates and survival rates of TP and DT is superior, and even if the 9mTc-MIBI test results were negative, relevant inspection programs or clinical observation is still needed.

关 键 词：晚期非小细胞肺癌 9mTc-MIBI检查 化疗 

分 类 号：R734[医药卫生—肿瘤]